Soleus Private Equity Fund III L.P. 13D and 13G filings for Nuvectis Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-06 11:19 am Purchase | 2026-08-04 | 13G | NUVECTIS PHARMA INC NVCT | Soleus Private Equity Fund III L.P. | 1,648,024 5.100% | 1,648,024 (New Position) | Filing |